Pancreatic Cancer Research

ResearcherDivision of Abdominal Tumor, Department of Medical Oncology, Cancer Center and State Key Laboratory of Biological Therapy, West China Hospital, Sichuan University, Chengdu, SichuanActive in the last 2 years

Dan Cao

Provisional: name at one institution (moderate confidence, 0.60), identity_conf@1As of 9 November 2026

Known by name at one institution; no external author ID yet. Sources: ClinicalTrials.gov.

Their work

Papers
0
Trials
3 (principal investigator on 3)
Grants
0
Labs led
0
Collaborators
0
Papers, trials and grants by year

2025: 1 trial · 2026: 2 trials

Trials 3

  1. JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure Principal investigator NCT07175389↗
  2. GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic PDAC Principal investigator NCT07802184↗
  3. A Study of GnP RegimenCombined With Serplulimab and Stereotactic Body Radiation Therapy as First-line Treatment for Locally Advanced Pancreatic Cancer Principal investigator NCT07101679↗

Closest collaborators

No collaborators recorded.

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.